We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVX:NASDAQNOVONIX Limited - American Depository Shares Analysis

Data as of 2026-06-12 - not real-time

$0.68

Latest Price

8/10Risk

Risk Level: High

Executive Summary

NOVONIX trades around $0.68, well below its 20‑day (≈$0.65) and 50‑day (≈$0.70) moving averages, signalling a short‑term bearish bias, while the RSI hovers near the neutral 50 mark and MACD remains bearish. Volume is increasing and the price sits just above the identified support level of $0.54, leaving limited downside cushion but also a clear barrier to further decline.
Fundamentally, the company reports modest revenue of roughly $5.6 M with negative growth, operating losses, and a substantial cash‑flow deficit, yet it carries a low price‑to‑book ratio (Risk is pronounced: the stock exhibits very high 30‑day volatility (~83 %), a computed beta above 2, and a historic drawdown near 80 %. These technical and financial stressors, combined with sector‑specific regulatory exposure and currency considerations, make the investment high‑risk, though the long‑term battery‑materials narrative could reward patient capital.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages indicating bearish momentum
  • Proximity to technical support limiting immediate downside
  • High volatility and beta amplifying short‑term risk

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst target price suggesting >300 % upside
  • Price‑to‑book below 1 indicating potential asset‑based value
  • Growing demand for battery anode materials and graphite resources

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic position in the expanding EV and energy‑storage market
  • Potential upside from the Mount Dromedary graphite project
  • Long‑term secular tailwinds for battery technology outweigh current earnings weakness

Key Metrics & Analysis

Financial Health

Revenue Growth-10.10%
P/E Ratio-3.0
ROE-61.97%
ROA-12.82%
Debt/Equity62.06
P/B Ratio0.9
Op. Cash Flow$-42199800
Free Cash Flow$-84516512
Industry P/E30.4

Technical Analysis

TrendBearish
RSI51.9
Support$0.54
Resistance$0.74
MA 20$0.65
MA 50$0.70
MA 200$1.09
MACDBearish
VolumeIncreasing
Fear & Greed Index86.71

Valuation

Target Price$3.00
Upside/Downside341.18%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.06
Volatility83.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.